z-logo
open-access-imgOpen Access
Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1
Author(s) -
Ute Raffetseder,
Thomas Rauen,
Sonja Djudjaj,
Matthias Kretzler,
Abdelaziz EnNia,
Frank Tacke,
Henning W. Zimmermann,
Peter J. Nelson,
Björn C. Frye,
Jürgen Floege,
Ioannis Stefanidis,
Christian Weber,
Peter R. Mertens
Publication year - 2008
Publication title -
kidney international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.499
H-Index - 276
eISSN - 1523-1755
pISSN - 0085-2538
DOI - 10.1038/ki.2008.457
Subject(s) - ccl5 , chemokine , monocyte , microbiology and biotechnology , ccl21 , cxcl11 , protein expression , cxcl10 , biology , chemistry , chemokine receptor , immunology , inflammation , t cell , immune system , biochemistry , gene , il 2 receptor
The Y-box protein-1 (YB-1) belongs to the family of cold shock proteins that have pleiotropic functions such as gene transcription, RNA splicing, and mRNA translation. YB-1 has a critical role in atherogenesis due to its regulatory effects on chemokine CCL5 (RANTES) gene transcription in vascular smooth muscle cells. Since CCL5 is a key mediator of kidney transplant rejection, we determined whether YB-1 is involved in allograft rejection by manipulating its expression. In human kidney biopsies, YB-1 transcripts were amplified 17-fold in acute and 21-fold in chronic allograft rejection with a close correlation between CCL5 and YB-1 mRNA expression in both conditions. Among three possible YB-1 binding sites in the CCL5 promoter, a critical element was mapped at -28/-10 bps. This site allowed up-regulation of CCL5 transcription in monocytic THP-1 and HUT78 T-cells and in human primary monocytes; however, it repressed transcription in differentiated macrophages. Conversely, YB-1 knockdown led to decreased CCL5 transcription and secretion in monocytic cells. We show that YB-1 is a cell-type specific regulator of CCL5 expression in infiltrating T-cells and monocytes/macrophages and acts as an adaptive controller of inflammation during kidney allograft rejection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom